The UK MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract.
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalisation due to heart failure or all-cause mortality for empagliflozin versus placebo.
Bespak have announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company.
Blackstone have announced a new collaboration with Moderna through a development and commercialisation funding agreement where funds managed by Blackstone Life Sciences and will provide up to $750 million to fund Moderna’s influenza program.
MSD have announced that the U.S. FDA has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension.
Otsuka Pharmaceutical Europe and H. Lundbeck A/S have announced that the European Commission has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the treatment of schizophrenia.
Corteria Pharmaceuticals have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure.
Novo Nordisk have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorisation for Awiqli for treatment of diabetes in adults.
Madrigal Pharmaceuticals have announced that the U.S. FDA has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH.
Biocon Biologics Limited have announced a long -term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.
